‘Me Too’ or Breakthrough? Exploring the Oncology Cell Therapy Pipeline

Posted by Katie Blodgett on Jun 26, 2019 8:00:00 AM

Last year, the American Society of Clinical Oncology (ASCO) designated adoptive cell immunotherapy the 2018 clinical cancer “advance of the year” following the 2017 FDA approvals of Kymriah (Novartis) and Yescarta (Kite, a Gilead company). In the year since, we have seen some incremental, notable approvals in the cell and gene therapy space, but we have yet to see additional cell therapy approvals in oncology. However, like a duck sailing smoothly across the water, the relative inactivity above the surface conceals a flurry of development activity taking place below the surface in the oncology pipeline.


>
Read More

The CAR-T First-Mover Advantage: Reality or Myth?

Posted by Sharon Karlsberg on Mar 12, 2019 8:00:00 AM

Robert Rovner co-wrote this blog post with Sharon Karlsberg. This article originally appeared in the January 2019 issue of OBR Green.

The “first-mover advantage” is something we’ve come to expect in the commercial world. The first to innovate and come to market usually reaps the greatest rewards, right? Facebook, Uber and Google improved on technology brought to market by actual first-movers MySpace, Sidecar and AltaVista, but then transcended them by addressing their weaknesses.


>
Read More

CAR-T Therapies: Improving on Today’s Reality and Planning for Tomorrow’s Innovation

Posted by Sharon Karlsberg on Jul 5, 2018 8:00:00 AM

Katie Blodgett and Robert Rovner co-authored this post with Sharon Karlsberg. 

Adoptive cell immunotherapy got top billing at this year’s American Society of Clinical Oncology (ASCO) meeting with its designation as the 2018 clinical cancer “Advance of the Year,” and for good reason. The first generation of chimeric antigen receptor T-cell (CAR-T) therapies, set in motion with the late 2017 approvals of Kymriah (Novartis) and Yescarta (Kite, a Gilead company), are among the most anticipated cancer breakthroughs to date.


>
Read More

Going Beyond the Buzz of CAR-T Therapy

Posted by Robert Rovner on Dec 21, 2017 10:21:09 AM

There’s no doubt that chimeric antigen receptor T-cell (CAR-T) therapies have been generating increased interest over the past four years at the American Society of Hematology’s (ASH) Annual Meeting. In 2014, 34 abstracts on CAR-T therapies were presented at ASH, a number that more than tripled to 110 abstracts by 2016. This year, more than 140 CAR-T abstracts were presented to a packed Georgia World Congress Center in Atlanta. While some questions about this novel approach to cancer treatment remain unanswered, one thing is for certain: CAR-T therapies are here to stay. 


>
Read More

Showdown at the ‘IO’ Corral

Posted by Malik Kaman on Apr 5, 2017 9:00:00 AM

Checkpoint inhibitors (CPIs) and chimeric antigen receptors (CAR-Ts) have transformed the field of cancer immunotherapy over the past five years. So far, these therapeutic approaches have operated in mutually exclusive landscapes with CPIs focusing on solid tumors and CAR-Ts focusing on hematologic malignancies, but now they’re entering each other’s spaces. As PD-1/L1 therapies enter hematology, and as CAR-Ts expand into solid tumors, should we expect a showdown at the immuno-oncology corral? 


>
Read More